Patents by Inventor Marcelo Bigal

Marcelo Bigal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATING REFRACTORY MIGRAINE
    Publication number: 20230242631
    Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: February 17, 2023
    Publication date: August 3, 2023
    Inventors: Marcelo Bigal, Ernesto Aycardi
  • Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
    Publication number: 20230235032
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: July 12, 2022
    Publication date: July 27, 2023
    Inventors: Marcelo Bigal, Sarah Walter, Henry Stern, Michael Chang
  • Treating headache comprising administering an antibody to calcitonin gene-related peptide
    Patent number: 11555064
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: January 17, 2023
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Marcelo Bigal, Sarah Walter, Henry Stern, Michael Chang
  • TREATING REFRACTORY MIGRAINE
    Publication number: 20220098287
    Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: May 5, 2021
    Publication date: March 31, 2022
    Inventors: Marcelo Bigal, Ernesto Aycardi
  • PREVENTING, TREATING, AND REDUCING (PERSISTENT) POST-TRAUMATIC HEADACHE
    Publication number: 20220048986
    Abstract: Disclosed herein are methods of treating or reducing incidence of post-traumatic headache and/or at least one secondary symptom associated with post-traumatic headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: April 5, 2021
    Publication date: February 17, 2022
    Inventor: Marcelo Bigal
  • Treating refractory migraine
    Patent number: 11028160
    Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: June 8, 2021
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Marcelo Bigal, Ernesto Aycardi
  • Treating refractory migraine
    Patent number: 11028161
    Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: June 8, 2021
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Marcelo Bigal, Ernesto Aycardi
  • TREATING REFRACTORY MIGRAINE
    Publication number: 20210040190
    Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: October 21, 2020
    Publication date: February 11, 2021
    Inventors: Marcelo Bigal, Ernesto Aycardi
  • TREATING REFRACTORY MIGRAINE
    Publication number: 20210040191
    Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: October 21, 2020
    Publication date: February 11, 2021
    Inventors: Marcelo Bigal, Ernesto Aycardi
  • Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
    Publication number: 20200377581
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: December 12, 2019
    Publication date: December 3, 2020
    Inventors: Marcelo Bigal, Sarah Walter, Henry Stern, Michael Chang
  • Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
    Publication number: 20200331991
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: November 7, 2019
    Publication date: October 22, 2020
    Inventors: Marcelo Bigal, Sarah Walter, Henry Stern, Michael Chang
  • TREATING REFRACTORY MIGRAINE
    Publication number: 20200223911
    Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: July 11, 2019
    Publication date: July 16, 2020
    Inventors: Marcelo Bigal, Ernesto Aycardi
  • PREVENTING, TREATING, AND REDUCING (PERSISTENT) POST-TRAUMATIC HEADACHE
    Publication number: 20200148761
    Abstract: Disclosed herein are methods of treating or reducing incidence of post-traumatic headache and/or at least one secondary symptom associated with post-traumatic headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: June 11, 2019
    Publication date: May 14, 2020
    Inventor: Marcelo Bigal
  • TREATING CLUSTER HEADACHE
    Publication number: 20200102377
    Abstract: Disclosed herein are methods of treating or reducing incidence of a cluster headache, e.g., chronic cluster headache and episodic cluster headache, and/or at least one secondary symptom associated with a cluster headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: May 15, 2019
    Publication date: April 2, 2020
    Inventors: Marcelo Bigal, Ernesto Aycardi, Orit Cohenbarak
  • Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
    Patent number: 10556945
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: February 11, 2020
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Marcelo Bigal, Sarah Walter, Henry Stern, Michael Chang
  • Treating headache comprising administering an antibody to calcitonin gene-related peptide
    Patent number: 10519224
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: December 31, 2019
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Marcelo Bigal, Sarah Walter, Henry Stern, Michael Chang
  • Treating refractory migraine
    Patent number: 10392434
    Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 27, 2019
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Marcelo Bigal, Ernesto Aycardi
  • Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
    Publication number: 20190031745
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: January 25, 2018
    Publication date: January 31, 2019
    Inventors: Marcelo Bigal, Sarah Walter, Henry Stern, Michael Chang
  • TREATING REFRACTORY MIGRAINE
    Publication number: 20180127490
    Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: September 22, 2017
    Publication date: May 10, 2018
    Inventors: Marcelo Bigal, Ernesto Aycardi
  • TREATING CLUSTER HEADACHE
    Publication number: 20180111984
    Abstract: Disclosed herein are methods of treating or reducing incidence of a cluster headache, e.g., chronic cluster headache and episodic cluster headache, and/or at least one secondary symptom associated with a cluster headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: September 22, 2017
    Publication date: April 26, 2018
    Inventors: Marcelo Bigal, Ernesto Aycardi, Orit Cohenbarak